New diabetes combo aims to beat standard care in Head-to-Head trial
NCT ID NCT06246799
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares two initial drug combinations for people recently diagnosed with type 2 diabetes. One group gets pioglitazone plus tirzepatide (Mounjaro), the other gets metformin plus sitagliptin. The study will track how well each combo lowers blood sugar and how long the effect lasts in 256 adults over several years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pioglitazone and tirzepatide (Mounjaro) combination
- What this could lead to
- If successful, this could show that starting with a pioglitazone and tirzepatide combo helps more people with new diabetes reach and maintain healthy blood sugar levels than the standard metformin and sitagliptin combo.
- What could go wrong
- This is a mid-stage trial with 256 people, so results may not apply to everyone. Both drug combos have side effects, and the study will not prove a cure—diabetes will still need ongoing management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (ADULT ONSET) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Health Science Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
University Health System Texas Diabetic Institute
RECRUITINGSan Antonio, Texas, 78207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.